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Introduction: Reteplase is a fibrin-specific thrombolytic drug and non-glycosylated 
modified recombinant form of human tissue plasminogen activator (t-PA). It is 
containing kringle-2 and serine protease domains but the epidermal growth factor 
and fibronectin finger domains are absent. The lack of finger domain in reteplase 
cause decrease fibrin specificity. Since the enhancing fibrin specificity is one of the 
aim for development new thrombolytic drug, due to decreasing side effect such as 
hemorrhage, also reteplase is non-glycosylated and can be produced in bacterial 
system at low cost, in this study a new generation of reteplase designed with more 
fibrin specificity.   
Methods and Results: According to the sequence of protein drugs
 
with more fibrin 
specificity, mutations in reteplase sequence consist of substitution mutation in 
Kringle 2 domains and adding sequence of mutated finger domain to reteplase 
sequence. 3D structure of this new reteplase was created by Modeller9.17 software 
and then simulated by Gromacs 5 software for 20 ns. Docking simulation was 
performed between new and wild reteplase with fibrin by HADDOCK server 
separately. The results showed that new reteplase has better interaction with fibrin 
compared with wild type (table1).  
Parameter Wild reteplase New  reteplase 
HADDOCK score
* 
-35.8 +/- 8.3 -43.2 +/- 21.3 
            *More negative score is better score 
 Conclusions: In this study a new generation of reteplase with more fibrin 
specificity was designed in silico. Since the production of reteplase has low cost 
compared with tPA, improvement its structure to desirable features such as 
increasing fibrin specificity, can be a way to achieve a favorable thrombolytic drug. 
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